ArticleMolecular biology reports2025
Investigation of a germline variant of uncertain significance (MRE11:c.1138C > T) identified by exome sequencing in a cancer-affected individual and co-segregation analysis in affected and unaffected family members.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCancer remains a significant global health concern, with familial cases often involving complex interactions between genetic predispositions and environmental factors. Variants of Uncertain Significance (VUS) pose challenges in genetic counseling and risk assessment, particularly in genes like MRE11, which plays a crucial role in DNA double-strand break repair and genomic stability. METHODS AND
resultsThis study aimed to investigate the effect of the MRE11 c.1138 C > T (p.Arg380Cys) variant in a family affected by familial cancer, focusing on its potential contribution to inherited cancer risk and the challenges it poses for genetic counseling in families with clustering of malignancies. Whole-exome sequencing was used to identify the variant, which was validated by Sanger sequencing. In silico protein modeling and bioinformatics analyses, including pathogenicity prediction tools like REVEL, SIFT, PolyPhen-2, and MutationTaster, were employed to assess the variant's functional effects. The MRE11 c.1138 C > T (p.Arg380Cys) variant was identified in a family with a history of breast, ovarian, and colorectal cancers.
conclusionsBioinformatics analyses suggested that this variant may destabilize the MRE11 nuclease domain, potentially impairing its function in DNA repair. Pathogenicity prediction tools consistently classified the variant as deleterious, although some family members with cancer did not carry the variant, indicating a complex interplay between genetic and environmental factors. The MRE11 p.Arg380Cys variant poses challenges in clinical interpretation due to its incomplete segregation within families. This pattern may reflect reduced penetrance, epistatic interactions with other genes (within MRN complex or others), or environmental influences.
Indexed as
Identifiers
40448789What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.